MCID: UTR032
MIFTS: 37

Uterine Body Mixed Cancer

Categories: Cancer diseases, Reproductive diseases

Aliases & Classifications for Uterine Body Mixed Cancer

MalaCards integrated aliases for Uterine Body Mixed Cancer:

Name: Uterine Body Mixed Cancer 12 14
Malignant Mixed Tumor, Not Otherwise Specified 69
Malignant Mixed Tumor of Corpus Uteri 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4114
NCIt 47 C6311
UMLS 69 C1334628

Summaries for Uterine Body Mixed Cancer

Disease Ontology : 12 A uterine corpus cancer that has material basis in more than one type of cell.

MalaCards based summary : Uterine Body Mixed Cancer, also known as malignant mixed tumor, not otherwise specified, is related to uterine carcinosarcoma and congenital disorder of glycosylation, type if. An important gene associated with Uterine Body Mixed Cancer is PIK3R2 (Phosphoinositide-3-Kinase Regulatory Subunit 2), and among its related pathways/superpathways are Class I MHC mediated antigen processing and presentation and Akt Signaling. The drugs Cisplatin and Doxorubicin have been mentioned in the context of this disorder. Affiliated tissues include liver, brain and kidney, and related phenotypes are cardiovascular system and growth/size/body region

Related Diseases for Uterine Body Mixed Cancer

Diseases related to Uterine Body Mixed Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 115)
id Related Disease Score Top Affiliating Genes
1 uterine carcinosarcoma 11.0
2 congenital disorder of glycosylation, type if 10.5 ERBB2 TP53
3 endocervicitis 10.5 ERBB2 TP53
4 split-hand/foot malformation 4 10.5 PPP2R1A TP53
5 animal phobia 10.5 ERBB2 TP53
6 extracranial neuroblastoma 10.4 ERBB2 TP53
7 blastema predominant kidney wilms' tumor 10.4 PGR TP53
8 cystic kidney disease 10.4 ERBB2 TP53
9 central nervous system organ benign neoplasm 10.4 PGR TP53
10 lung adenoma 10.4 PGR TP53
11 brenner tumor of the vagina 10.4 ERBB2 TP53
12 brenner tumor of ovary 10.4 ERBB2 TP53
13 orbital lymphoma 10.4 ERBB2 TP53
14 breast myoepithelial neoplasm 10.4 PGR TP53
15 leiomyoma cutis 10.4 PGR TP53
16 intestinal perforation 10.4 PGR TP53
17 prostatic acinar adenocarcinoma 10.4 PGR TP53
18 intraductal breast myoepitheliosis 10.4 PGR TP53
19 fallopian tube squamous cell carcinoma 10.4 KIT TP53
20 villous adenocarcinoma 10.4 ERBB2 TP53
21 gastritis 10.4 ERBB2 PGR
22 ovarian mesodermal adenosarcoma 10.4 PGR TP53
23 group b strep disease in newborns 10.4 ERBB2 TP53
24 breast pericanalicular fibroadenoma 10.4 PGR TP53
25 glaucoma, hereditary 10.4 ERBB2 PGR
26 chest wall lymphoma 10.4 PGR TP53
27 skin sarcoma 10.4 ERBB2 PGR
28 her2-receptor negative breast cancer 10.4 ERBB2 PGR
29 spinal cancer 10.4 ERBB2 PGR
30 subglottis verrucous carcinoma 10.4 ERBB2 PGR
31 retinal detachment 10.4 PGR TP53
32 central nervous system germ cell tumor 10.4 PGR TP53
33 gastric tubular adenocarcinoma 10.4 ERBB2 PGR
34 her2-receptor positive breast cancer 10.4 ERBB2 PGR
35 pancreatic agenesis 10.3 KIT TP53
36 gastroesophageal junction adenocarcinoma 10.3 ERBB2 PGR
37 hip subluxation 10.3 ERBB2 TP53
38 kallmann syndrome 10.3 ERBB2 PGR
39 penis squamous cell carcinoma 10.3 ERBB2 PGR
40 plasmodium ovale malaria 10.3 KIT TP53
41 dmd-related dilated cardiomyopathy 10.3 ERBB2 PGR
42 mannose-binding lectin protein deficiency 10.3 KIT PGR
43 pacinian tumor 10.3 KIT TP53
44 superficial basal cell carcinoma 10.3 KIT PGR
45 extra-adrenal pheochromocytoma 10.3 PPP2R1A TP53
46 malignant thyroid stimulating hormone producing neoplasm of pituitary gland 10.3 ERBB2 PGR
47 pseudounicornuate uterus 10.3 KIT PGR
48 enamel hypoplasia cataract hydrocephaly 10.3 KIT TP53
49 thyroid angiosarcoma 10.3 KIT PGR
50 exertional headache 10.3 ERBB2 KIT

Graphical network of the top 20 diseases related to Uterine Body Mixed Cancer:



Diseases related to Uterine Body Mixed Cancer

Symptoms & Phenotypes for Uterine Body Mixed Cancer

MGI Mouse Phenotypes related to Uterine Body Mixed Cancer:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.88 ERBB2 KIT PGR PIK3R2 SOX7 TP53
2 growth/size/body region MP:0005378 9.87 PPP2R1A SOX7 TP53 ERBB2 KIT PIK3R2
3 endocrine/exocrine gland MP:0005379 9.85 CD109 ERBB2 KIT PGR SOX7 TP53
4 integument MP:0010771 9.73 CD109 ERBB2 KIT PGR PKP3 TP53
5 muscle MP:0005369 9.63 ERBB2 KIT PGR PIK3R2 SOX7 TP53
6 neoplasm MP:0002006 9.43 ERBB2 KIT PGR PIK3R2 PPP2R1A TP53
7 normal MP:0002873 9.1 ERBB2 KIT PGR PKP3 PPP2R1A TP53

Drugs & Therapeutics for Uterine Body Mixed Cancer

Drugs for Uterine Body Mixed Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 158)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
2
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
3
Lenograstim Approved Phase 3,Phase 2,Phase 1 135968-09-1
4
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
5
Bleomycin Approved Phase 3 11056-06-7 5360373
6
Cortisone acetate Approved Phase 3,Phase 2 1950-04-4, 50-04-4 5745
7
Cyclophosphamide Approved, Investigational Phase 3,Phase 2 50-18-0, 6055-19-2 2907
8
Cytarabine Approved, Investigational Phase 3,Phase 2 147-94-4 6253
9
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2 50-02-2 5743
10
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
11
Prednisone Approved, Vet_approved Phase 3,Phase 2 53-03-2 5865
12
Vincristine Approved, Investigational Phase 3,Phase 2 2068-78-2, 57-22-7 5978
13
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
14
Ondansetron Approved Phase 3 99614-02-5 4595
15
Dactinomycin Approved Phase 3,Phase 2 50-76-0 2019 457193
16
Everolimus Approved Phase 3,Phase 2,Phase 1 159351-69-6 6442177
17
Irinotecan Approved, Investigational Phase 3,Phase 2 97682-44-5, 100286-90-6 60838
18
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
19
Sirolimus Approved, Investigational Phase 3,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
20
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
21 Thiotepa Approved Phase 3,Phase 2 52-24-4 5453
22
Fluorouracil Approved Phase 3 51-21-8 3385
23
Levoleucovorin Approved Phase 3,Phase 2 68538-85-2
24
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
25
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 59-30-3 6037
26
leucovorin Approved, Nutraceutical Phase 3,Phase 2 58-05-9 143 6006
27
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
28
Camptothecin Experimental Phase 3,Phase 2 7689-03-4
29 Adjuvants, Immunologic Phase 3,Phase 2,Phase 1
30 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
31 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
32 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
33 Antimitotic Agents Phase 3,Phase 2,Phase 1
34 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
35 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
36 Alkylating Agents Phase 3,Phase 2
37 Antiemetics Phase 3,Phase 2
38 Anti-Infective Agents Phase 3,Phase 2,Phase 1
39 Anti-Inflammatory Agents Phase 3,Phase 2
40 Antimetabolites Phase 3,Phase 2
41 Antimetabolites, Antineoplastic Phase 3,Phase 2
42 Antineoplastic Agents, Hormonal Phase 3,Phase 2
43 Antirheumatic Agents Phase 3,Phase 2
44 Antiviral Agents Phase 3,Phase 2,Phase 1
45 Autonomic Agents Phase 3,Phase 2
46 BB 1101 Phase 3,Phase 2
47
Cortisone Phase 3,Phase 2 53-06-5 222786
48 Dermatologic Agents Phase 3,Phase 2
49 Dexamethasone acetate Phase 3,Phase 2 1177-87-3
50 Etoposide phosphate Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 51)

id Name Status NCT ID Phase Drugs
1 Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer Completed NCT00006011 Phase 3 Doxorubicin Hydrochloride;Cisplatin;Paclitaxel
2 Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease Completed NCT00025259 Phase 3 Cisplatin;Cyclophosphamide;Cytarabine;Dexamethasone;Doxorubicin Hydrochloride;Etoposide;Prednisone;Vincristine Sulfate Liposome
3 Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy Completed NCT01346267 Phase 3
4 Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor Completed NCT00379340 Phase 3 doxorubicin hydrochloride;liposomal vincristine sulfate;cyclophosphamide;etoposide
5 Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor Completed NCT00352534 Phase 3 vincristine sulfate;doxorubicin hydrochloride
6 Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer Recruiting NCT00980460 Phase 3 Cisplatin;Doxorubicin Hydrochloride;Fluorouracil;Irinotecan Hydrochloride;Temsirolimus;Vincristine Sulfate
7 Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System Active, not recruiting NCT00653068 Phase 3 methotrexate;leucovorin calcium;etoposide;cyclophosphamide;cisplatin;carboplatin;thiotepa;vincristine sulfate
8 Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor Active, not recruiting NCT00945009 Phase 3 Doxorubicin Hydrochloride;Vincristine Sulfate;Carboplatin;Cyclophosphamide;Etoposide Phosphate
9 Multicenter Trial With PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors Completed NCT00815945 Phase 2 PegLiposomal Doxorubicin;Carboplatin
10 Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer Completed NCT01247571 Phase 2 Pazopanib Hydrochloride
11 Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer Completed NCT00114218 Phase 2 Gemcitabine Hydrochloride;Docetaxel
12 Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus Completed NCT00025506 Phase 2 Thalidomide
13 Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus Completed NCT00064025 Phase 2 Medroxyprogesterone
14 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
15 Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01225887 Phase 2 Nintedanib
16 Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01642082 Phase 2
17 Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01011933 Phase 2 Selumetinib
18 Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT00820898 Phase 2 Gemcitabine Hydrochloride
19 Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer Completed NCT01307631 Phase 2 Akt Inhibitor MK2206
20 Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01132820 Phase 2 Cediranib Maleate
21 Gemcitabine and Vinorelbine in Treating Young Patients With Recurrent or Refractory Hodgkin's Lymphoma Completed NCT00070304 Phase 2 gemcitabine hydrochloride;vinorelbine tartrate
22 Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma Completed NCT01462695 Phase 2 Sunitinib Malate
23 Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer Completed NCT01210222 Phase 2
24 Neoadjuvant Chemotherapy With or Without Second-Look Surgery Followed by Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Intracranial Germ Cell Tumors Completed NCT00047320 Phase 2 carboplatin;etoposide;ifosfamide;thiotepa
25 Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma Completed NCT01222715 Phase 2 Cyclophosphamide;Temsirolimus;Vinorelbine Tartrate
26 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01154452 Phase 1, Phase 2 Gamma-Secretase Inhibitor RO4929097;Vismodegib
27 Vaccine Therapy and Biological Therapy in Treating Patients With Advanced Cancer Completed NCT00019084 Phase 2
28 Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors Completed NCT00335556 Phase 2 Doxorubicin Hydrochloride;Irinotecan Hydrochloride;Cyclophosphamide;Etoposide;Carboplatin;Vincristine Sulfate
29 Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer Completed NCT01502410 Phase 2 sorafenib tosylate
30 Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia Completed NCT01154816 Phase 2 Alisertib
31 Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer Recruiting NCT03018249 Phase 2 Entinostat;Medroxyprogesterone Acetate
32 Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer Recruiting NCT00492778 Phase 2 Cisplatin
33 Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer Recruiting NCT02874430 Phase 2 Metformin Hydrochloride;Doxycycline
34 Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement Recruiting NCT02828358 Phase 2 Azacitidine;Cyclophosphamide;Cytarabine;Daunorubicin Hydrochloride;Dexamethasone;Hydrocortisone Sodium Succinate;Leucovorin Calcium;Mercaptopurine;Methotrexate;Pegaspargase;Prednisolone;Thioguanine;Vincristine Sulfate
35 Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer Active, not recruiting NCT00478426 Phase 2 Sunitinib Malate
36 Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer Active, not recruiting NCT00888173 Phase 2 Brivanib Alaninate
37 Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer Active, not recruiting NCT00977574 Phase 2 Carboplatin;Ixabepilone;Paclitaxel;Temsirolimus
38 Cabozantinib-S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer Suspended NCT01935934 Phase 2 Cabozantinib S-malate
39 Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer Suspended NCT02728258 Phase 2 Copanlisib
40 Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors Completed NCT01522820 Phase 1 Sirolimus
41 Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer Completed NCT00575952 Phase 1 Cisplatin;Doxorubicin Hydrochloride;Paclitaxel
42 VSV-hIFNbeta-NIS in Treating Patients With Stage IV or Recurrent Endometrial Cancer Recruiting NCT03120624 Phase 1 Technetium Tc-99m Sodium Pertechnetate
43 Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer Active, not recruiting NCT01935973 Phase 1 Akt Inhibitor GSK2141795;Trametinib
44 Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer Active, not recruiting NCT01440998 Phase 1 Carboplatin;Dasatinib;Paclitaxel
45 Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery or Gynecological Cancers Suspended NCT02020707 Phase 1 Paclitaxel Albumin-Stabilized Nanoparticle Formulation
46 Collecting Tumor Samples From Patients With Gynecological Tumors Completed NCT00897442
47 Evaluating Dactinomycin and Vincristine in Young Patients With Cancer Completed NCT00674193
48 Collecting and Storing Tissue From Young Patients With Cancer Recruiting NCT00898755
49 Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma Recruiting NCT01000753
50 Study of Kidney Tumors in Younger Patients Recruiting NCT00898365

Search NIH Clinical Center for Uterine Body Mixed Cancer

Genetic Tests for Uterine Body Mixed Cancer

Anatomical Context for Uterine Body Mixed Cancer

MalaCards organs/tissues related to Uterine Body Mixed Cancer:

39
Liver, Brain, Kidney, Endothelial, Uterus, Bone, Thyroid

Publications for Uterine Body Mixed Cancer

Variations for Uterine Body Mixed Cancer

Expression for Uterine Body Mixed Cancer

Search GEO for disease gene expression data for Uterine Body Mixed Cancer.

Pathways for Uterine Body Mixed Cancer

Pathways related to Uterine Body Mixed Cancer according to GeneCards Suite gene sharing:

(show all 21)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.17 ERBB2 KIT PIK3R2 PPP2R1A TP53
2
Show member pathways
13.11 ERBB2 KIT PIK3R2 PPP2R1A TP53
3
Show member pathways
13.03 ERBB2 KIT PIK3R2 PPP2R1A TP53
4 12.39 KIT PIK3R2 PPP2R1A TP53
5
Show member pathways
12.25 ERBB2 PIK3R2 TP53
6 12.22 ERBB2 KIT PIK3R2 TP53
7
Show member pathways
12.2 ERBB2 PIK3R2 TP53
8
Show member pathways
12.18 PIK3R2 PPP2R1A TP53
9
Show member pathways
12.12 ERBB2 KIT PGR PIK3R2 TP53
10
Show member pathways
12.07 PGR PIK3R2 PPP2R1A
11
Show member pathways
12.03 ERBB2 PIK3R2 TP53
12 11.99 ERBB2 PIK3R2 TP53
13
Show member pathways
11.99 ERBB2 KIT PIK3R2 PPP2R1A TP53
14 11.77 PIK3R2 PPP2R1A TP53
15
Show member pathways
11.73 ERBB2 PIK3R2 TP53
16 11.68 PIK3R2 PPP2R1A TP53
17 11.64 ERBB2 PIK3R2 TP53
18 11.3 ERBB2 PIK3R2 TP53
19 11.2 ERBB2 PIK3R2 TP53
20 10.84 PIK3R2 TP53
21 10.74 ERBB2 KIT PIK3R2 TP53

GO Terms for Uterine Body Mixed Cancer

Biological processes related to Uterine Body Mixed Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.56 ERBB2 KIT PKP3 TP53
2 phosphatidylinositol phosphorylation GO:0046854 9.33 ERBB2 KIT PIK3R2
3 phosphatidylinositol 3-kinase signaling GO:0014065 9.32 ERBB2 PIK3R2
4 regulation of phosphatidylinositol 3-kinase signaling GO:0014066 9.13 ERBB2 KIT PIK3R2
5 phosphatidylinositol-mediated signaling GO:0048015 8.92 ERBB2 KIT PIK3R2 TP53

Molecular functions related to Uterine Body Mixed Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein heterodimerization activity GO:0046982 9.56 ERBB2 PIK3R2 PPP2R1A TP53
2 signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 9.16 ERBB2 KIT
3 protein phosphatase binding GO:0019903 9.13 ERBB2 PIK3R2 TP53
4 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 8.8 ERBB2 KIT PIK3R2

Sources for Uterine Body Mixed Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....